Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Assets Average (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Assets Average data on record, last reported at $85.0 million in Q3 2025.

  • For Q3 2025, Assets Average rose 37.74% year-over-year to $85.0 million; the TTM value through Sep 2025 reached $85.0 million, up 37.74%, while the annual FY2024 figure was $57.2 million, 0.59% up from the prior year.
  • Assets Average reached $85.0 million in Q3 2025 per CRVS's latest filing, up from $74.4 million in the prior quarter.
  • Across five years, Assets Average topped out at $96.9 million in Q2 2022 and bottomed at $42.8 million in Q1 2024.
  • Average Assets Average over 4 years is $66.2 million, with a median of $63.5 million recorded in 2023.
  • Peak YoY movement for Assets Average: crashed 40.03% in 2023, then soared 49.87% in 2025.
  • A 4-year view of Assets Average shows it stood at $74.3 million in 2022, then plummeted by 34.39% to $48.7 million in 2023, then surged by 31.0% to $63.9 million in 2024, then soared by 33.05% to $85.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $85.0 million in Q3 2025, $74.4 million in Q2 2025, and $64.2 million in Q1 2025.